endovascular.es

Título: STENTYS Reaches 10,000 Self-Apposing Stent implantations
Fecha: 03-09-2014
STENTYS (FR0010949404 – STNT) (Paris:STNT), a medical technology company commercializing the world’s first and only Self-Apposing® Stent to treat acute myocardial infarction (AMI), today announced that the Self-Apposing stent has been implanted over 10,000 times in patients worldwide. This milestone further illustrates the popularity of STENTYS’ technology among cardiologists in Europe and a growing number of regions globally.
The Self-Apposing stent was first implanted during a “first-in-man” study in 2007. Since then, STENTYS has enrolled more than 2,000 patients in clinical evaluations and conducted nine international clinical trials that have demonstrated the benefits of Self-Apposing technology over conventional options. The company has expanded marketing in Europe, the Middle East, Asia and South America, and is currently expecting approval of its Sirolimus-eluting stent in Europe before year end.
The STENTYS Self-Apposing Stent solves the stent-sizing dilemma that cardiologists are confronted with when treating heart attack patients with conventional stents. The STENTYS Self-Apposing Stent’s flexible, self expanding design takes the shape of the patient’s unique vessel anatomy and apposes to the irregular contours of a blood vessel, in particular after an AMI as the vessel dilates and the clot dissolves, thereby eliminating malapposition and the major complications seen with conventional stents.
“The 10,000th stent implanted represents a major milestone in the company’s history,” said Gonzague Issenmann, CEO and co-founder of STENTYS. “We look forward to educating an even greater number of cardiologists and continuing our expansion to the benefit of all the patients worldwide that cannot be optimally treated with conventional balloon expandable stents.”
Fuente: endovascular.es

endovasculares.es